Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Oral bicalutamide is safe and effective for female hair loss.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.

Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.

Flutamide and its metabolite can effectively reduce androgen effects.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

Flutamide effectively treats female pattern hair loss long-term with low doses being safe for the liver.

Bicalutamide shows promise for treating female hair loss.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Flutamide, delivered by solid lipid nanoparticles, could potentially treat hair loss.

A woman's adrenal tumor disappeared after treatment with cyproterone acetate.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.

Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.